Wellington Management Group LLP Has $775,000 Holdings in Agios Pharmaceuticals, Inc. $AGIO

Wellington Management Group LLP lessened its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 96.7% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,875 shares of the biopharmaceutical company's stock after selling 620,611 shares during the period. Wellington Management Group LLP's holdings in Agios Pharmaceuticals were worth $775,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC increased its stake in shares of Agios Pharmaceuticals by 66.8% during the first quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company's stock worth $1,498,000 after purchasing an additional 20,625 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Agios Pharmaceuticals by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company's stock valued at $1,274,000 after purchasing an additional 2,920 shares during the period. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals in the 1st quarter valued at $40,000. Goldman Sachs Group Inc. grew its holdings in Agios Pharmaceuticals by 16.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company's stock valued at $19,299,000 after buying an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP acquired a new position in Agios Pharmaceuticals in the 1st quarter valued at $597,000.

Insider Activity

In other news, insider Sarah Gheuens sold 30,000 shares of the business's stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the transaction, the insider owned 54,645 shares of the company's stock, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.40% of the company's stock.

Agios Pharmaceuticals Trading Down 0.1%

NASDAQ AGIO opened at $33.60 on Friday. The firm's 50 day simple moving average is $35.26 and its 200 day simple moving average is $32.03. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of -4.79 and a beta of 0.60. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The firm had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. On average, equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -5.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AGIO has been the subject of a number of research reports. Royal Bank Of Canada lifted their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a "sector perform" rating in a report on Tuesday, July 7th. Weiss Ratings restated a "sell (d)" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Truist Financial lowered their price target on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. JPMorgan Chase & Co. lifted their price objective on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, August 7th. Finally, HC Wainwright lifted their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $41.25.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.